XML 14 R2.htm IDEA: XBRL DOCUMENT v3.25.1
Pay vs Performance Disclosure - USD ($)
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Pay vs Performance Disclosure          
Pay vs Performance Disclosure, Table
Year
​ ​
Summary
Compensation
Table Total
for Jack
Khattar(1)
($)
​ ​
Compensation
Actually
Paid to
Jack
Khattar(1)(2)(3)
($)
​ ​
Average
Summary
Compensation
Table Total
for Non-PEO
NEOs(1)
($)
​ ​
Average
Compensation
Actually
Paid to
Non-PEO
NEOs(1)(2)(3)
($)
​ ​
Value of Initial Fixed
$100 Investment
based on:(4)
​ ​
Net
Earnings
($ Millions)
​ ​
Gross
Product
Sales
($ Millions)(5)
​
​
Total
Shareholder
Return
(“TSR”)
($)
​ ​
Peer
Group
TSR
($)
​
(a)
​ ​
(b)
​ ​
(c)
​ ​
(d)
​ ​
(e)
​ ​
(f)
​ ​
(g)
​ ​
(h)
​ ​
(i)
​
2024
​ ​ ​ ​ 17,848,004 ​ ​ ​ ​ ​ 14,445,533 ​ ​ ​ ​ ​ 2,004,458 ​ ​ ​ ​ ​ 1,685,133 ​ ​ ​ ​ ​ 152.45 ​ ​ ​ ​ ​ 118.20 ​ ​ ​ ​ ​ 73.9 ​ ​ ​ ​ ​ 1,101 ​ ​
2023
​ ​ ​ ​ 13,278,093 ​ ​ ​ ​ ​ 13,491,498 ​ ​ ​ ​ ​ 1,806,329 ​ ​ ​ ​ ​ 1,691,851 ​ ​ ​ ​ ​ 122.01 ​ ​ ​ ​ ​ 118.87 ​ ​ ​ ​ ​ 1.3 ​ ​ ​ ​ ​ 1,071 ​ ​
2022
​ ​ ​ ​ 10,012,717 ​ ​ ​ ​ ​ 11,056,323 ​ ​ ​ ​ ​ 1,167,214 ​ ​ ​ ​ ​ 1,433,071 ​ ​ ​ ​ ​ 150.38 ​ ​ ​ ​ ​ 113.65 ​ ​ ​ ​ ​ 60.7 ​ ​ ​ ​ ​ 1,181 ​ ​
2021
​ ​ ​ ​ 8,116,721 ​ ​ ​ ​ ​ 7,914,950 ​ ​ ​ ​ ​ 979,005 ​ ​ ​ ​ ​ 601,468 ​ ​ ​ ​ ​ 122.93 ​ ​ ​ ​ ​ 126.45 ​ ​ ​ ​ ​ 53.4 ​ ​ ​ ​ ​ 1,021 ​ ​
2020
​ ​ ​ ​ 6,669,046 ​ ​ ​ ​ ​ 6,134,966 ​ ​ ​ ​ ​ 1,204,624 ​ ​ ​ ​ ​ 939,602 ​ ​ ​ ​ ​ 106.07 ​ ​ ​ ​ ​ 126.42 ​ ​ ​ ​ ​ 127.0 ​ ​ ​ ​ ​ 951 ​ ​
1.   Jack Khattar was our PEO for each year presented. The individuals comprising the Non-PEO NEOs for each year presented are listed below.
​
2020
​ ​
2021
​ ​
2022-2024
​
​
James P. Kelly
​ ​
Timothy C. Dec
​ ​
Timothy C. Dec
​
​
Stefan K.F. Schwabe, M.D., Ph.D.
​ ​
Jonathan Rubin, MD
​ ​
Jonathan Rubin, MD
​
​
Padmanabh P. Bhatt, Ph.D.
​ ​
Padmanabh P. Bhatt, Ph.D.
​ ​
Padmanabh P. Bhatt, Ph.D.
​
​
Tami Martin, R.N., Esq.
​ ​
Tami Martin, R.N., Esq.
​ ​
Frank Mottola
​
​
Gregory S. Patrick
​ ​
James P. Kelly
​ ​
—
​
2.   The amounts shown for Compensation Actually Paid have been calculated in accordance with Item 402(v) of Regulation S-K and do not reflect compensation actually earned, realized, or received by the Company’s NEOs. These amounts reflect the Summary Compensation Table Total with certain adjustments as described in footnote 3 below.
3.   Compensation Actually Paid reflects the exclusions and inclusions of certain amounts for the PEO and the Non-PEO NEOs as set forth below. Equity values are calculated in accordance with FASB ASC Topic 718. Amounts in the Exclusion of Stock Awards and Option Awards column are the totals from the Stock Awards and Option Awards columns set forth in the Summary Compensation Table. Amounts in the Inclusion of Equity Values column are set forth in the table further below.
Year
​ ​
Summary
Compensation Table
Total for
Jack Khattar
($)
​ ​
Exclusion of
Stock Awards and
Option Awards for
Jack Khattar
($)
​ ​
Inclusion of
Equity Values for
Jack Khattar
($)
​ ​
Compensation
Actually Paid
to Jack Khattar
($)
​
2024 ​ ​ ​ ​ 17,848,004 ​ ​ ​ ​ ​ (10,766,439) ​ ​ ​ ​ ​ 7,363,968 ​ ​ ​ ​ ​ 14,445,533 ​ ​
Year
​ ​
Average Summary
Compensation Table
Total for Non-PEO
NEOs
($)
​ ​
Average Exclusion of
Stock Awards and
Option Awards for
Non-PEO NEOs
($)
​ ​
Average Inclusion of
Equity Values for
Non-PEO NEOs
($)
​ ​
Average
Compensation
Actually Paid
to Non-PEO
NEOs
($)
​
2024
​ ​ ​ ​ 2,004,458 ​ ​ ​ ​ ​ (922,579) ​ ​ ​ ​ ​ 603,254 ​ ​ ​ ​ ​ 1,685,133 ​ ​
The amounts in the Inclusion of Equity Values in the tables above are derived from the amounts set forth in the following tables:
Year
​ ​
Year-End
Fair Value of
Equity
Awards
Granted
During Year
That
Remained
Unvested as
of Last Day
of Year for
Jack Khattar
($)
​ ​
Change in
Fair Value
from Last Day
of Prior Year
to Last Day of
Year of
Unvested
Equity
Awards for
Jack Khattar
($)
​ ​
Vesting-Date
Fair Value of
Equity
Awards
Granted
During Year
that Vested
During Year
for Jack
Khattar
($)
​ ​
Change in
Fair Value
from Last
Day of Prior
Year to
Vesting Date
of Unvested
Equity
Awards that
Vested
During Year
for Jack
Khattar
($)
​ ​
Fair Value at
Last Day of
Prior Year of
Equity
Awards
Forfeited
During Year
for Jack
Khattar
($)
​ ​
Total −
Inclusion
of
Equity
Values for
Jack
Khattar
($)
​
2024
​ ​ ​ ​ 10,504,593 ​ ​ ​ ​ ​ (2,103,882) ​ ​ ​ ​ ​ 1,375,198 ​ ​ ​ ​ ​ (2,411,941) ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ 7,363,968 ​ ​
Year
​ ​
Average
Year-End
Fair Value of
Equity
Awards
Granted
During Year
That
Remained
Unvested as of
Last Day of
Year for Non-
PEO NEOs
($)
​ ​
Average
Change in
Fair Value
from Last
Day of Prior
Year to Last
Day of Year
of Unvested
Equity
Awards for
Non-PEO
NEOs
($)
​ ​
Average
Vesting-Date
Fair Value of
Equity
Awards
Granted
During Year
that Vested
During Year
for Non-PEO
NEOs
($)
​ ​
Average
Change in
Fair Value
from Last
Day of Prior
Year to
Vesting Date
of Unvested
Equity
Awards that
Vested During
Year for Non-
PEO NEOs
($)
​ ​
Average Fair
Value at Last
Day of Prior
Year of
Equity
Awards
Forfeited
During Year
for Non-PEO
NEOs
($)
​ ​
Total −
Average
Inclusion
of
Equity
Values
for Non-
PEO
NEOs
($)
​
2024
​ ​ ​ ​ 1,006,487 ​ ​ ​ ​ ​ (168,509) ​ ​ ​ ​ ​ 58,719 ​ ​ ​ ​ ​ (293,443) ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ 603,254 ​ ​
4.   The Peer Group TSR set forth in this table utilizes the Nasdaq Biotechnology Index, which we also utilize in the stock performance graph required by Item 201(e) of Regulation S-K included in our Annual Report for the year ended December 31, 2024. The comparison assumes $100 was invested for the period starting December 31, 2019, through the end of the listed year in the Company and in the Nasdaq Biotechnology Index, respectively. Historical stock performance is not necessarily indicative of future stock performance. Cumulative TSR is calculated by dividing (i) the sum of (a) the cumulative amount of any dividends for the measurement period and (b) the change in the company’s share price during the measurement period by (ii) the share price at the beginning of the measurement period. This assumes dividend reinvestment.
5.   We determined Gross Product Sales to be the most important financial performance measure used to link Company performance to Compensation Actually Paid to our PEO and Non-PEO NEOs in 2024, 2023 and 2022. This performance measure may not have been the most important financial performance measure for years prior and we may determine a different financial performance measure to be the most important financial performance measure in future years. The Company’s net revenues consist of net product sales and royalties, licensing and other revenues. The Company recognizes revenue from product sales in an amount that reflects the consideration the Company expects to ultimately receive in exchange for those goods. The Company recognizes gross product sales when its customers take control of its products, including title and ownership. Product sales are recorded net of various forms of variable consideration, including: provision for estimated rebates; provision for estimated future product returns; and an estimated provision for discounts. These are collectively considered “sales deductions.” These amounts are treated as variable consideration, estimated and recognized as a reduction of the transaction price at the time of sale.
       
Company Selected Measure Name Gross Product Sales        
Named Executive Officers, Footnote
1.   Jack Khattar was our PEO for each year presented. The individuals comprising the Non-PEO NEOs for each year presented are listed below.
​
2020
​ ​
2021
​ ​
2022-2024
​
​
James P. Kelly
​ ​
Timothy C. Dec
​ ​
Timothy C. Dec
​
​
Stefan K.F. Schwabe, M.D., Ph.D.
​ ​
Jonathan Rubin, MD
​ ​
Jonathan Rubin, MD
​
​
Padmanabh P. Bhatt, Ph.D.
​ ​
Padmanabh P. Bhatt, Ph.D.
​ ​
Padmanabh P. Bhatt, Ph.D.
​
​
Tami Martin, R.N., Esq.
​ ​
Tami Martin, R.N., Esq.
​ ​
Frank Mottola
​
​
Gregory S. Patrick
​ ​
James P. Kelly
​ ​
—
​
       
Peer Group Issuers, Footnote
4.   The Peer Group TSR set forth in this table utilizes the Nasdaq Biotechnology Index, which we also utilize in the stock performance graph required by Item 201(e) of Regulation S-K included in our Annual Report for the year ended December 31, 2024. The comparison assumes $100 was invested for the period starting December 31, 2019, through the end of the listed year in the Company and in the Nasdaq Biotechnology Index, respectively. Historical stock performance is not necessarily indicative of future stock performance. Cumulative TSR is calculated by dividing (i) the sum of (a) the cumulative amount of any dividends for the measurement period and (b) the change in the company’s share price during the measurement period by (ii) the share price at the beginning of the measurement period. This assumes dividend reinvestment.
       
PEO Total Compensation Amount $ 17,848,004 $ 13,278,093 $ 10,012,717 $ 8,116,721 $ 6,669,046
PEO Actually Paid Compensation Amount $ 14,445,533 13,491,498 11,056,323 7,914,950 6,134,966
Adjustment To PEO Compensation, Footnote
3.   Compensation Actually Paid reflects the exclusions and inclusions of certain amounts for the PEO and the Non-PEO NEOs as set forth below. Equity values are calculated in accordance with FASB ASC Topic 718. Amounts in the Exclusion of Stock Awards and Option Awards column are the totals from the Stock Awards and Option Awards columns set forth in the Summary Compensation Table. Amounts in the Inclusion of Equity Values column are set forth in the table further below.
Year
​ ​
Summary
Compensation Table
Total for
Jack Khattar
($)
​ ​
Exclusion of
Stock Awards and
Option Awards for
Jack Khattar
($)
​ ​
Inclusion of
Equity Values for
Jack Khattar
($)
​ ​
Compensation
Actually Paid
to Jack Khattar
($)
​
2024 ​ ​ ​ ​ 17,848,004 ​ ​ ​ ​ ​ (10,766,439) ​ ​ ​ ​ ​ 7,363,968 ​ ​ ​ ​ ​ 14,445,533 ​ ​
The amounts in the Inclusion of Equity Values in the tables above are derived from the amounts set forth in the following tables:
Year
​ ​
Year-End
Fair Value of
Equity
Awards
Granted
During Year
That
Remained
Unvested as
of Last Day
of Year for
Jack Khattar
($)
​ ​
Change in
Fair Value
from Last Day
of Prior Year
to Last Day of
Year of
Unvested
Equity
Awards for
Jack Khattar
($)
​ ​
Vesting-Date
Fair Value of
Equity
Awards
Granted
During Year
that Vested
During Year
for Jack
Khattar
($)
​ ​
Change in
Fair Value
from Last
Day of Prior
Year to
Vesting Date
of Unvested
Equity
Awards that
Vested
During Year
for Jack
Khattar
($)
​ ​
Fair Value at
Last Day of
Prior Year of
Equity
Awards
Forfeited
During Year
for Jack
Khattar
($)
​ ​
Total −
Inclusion
of
Equity
Values for
Jack
Khattar
($)
​
2024
​ ​ ​ ​ 10,504,593 ​ ​ ​ ​ ​ (2,103,882) ​ ​ ​ ​ ​ 1,375,198 ​ ​ ​ ​ ​ (2,411,941) ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ 7,363,968 ​ ​
       
Non-PEO NEO Average Total Compensation Amount $ 2,004,458 1,806,329 1,167,214 979,005 1,204,624
Non-PEO NEO Average Compensation Actually Paid Amount $ 1,685,133 1,691,851 1,433,071 601,468 939,602
Adjustment to Non-PEO NEO Compensation Footnote
3.   Compensation Actually Paid reflects the exclusions and inclusions of certain amounts for the PEO and the Non-PEO NEOs as set forth below. Equity values are calculated in accordance with FASB ASC Topic 718. Amounts in the Exclusion of Stock Awards and Option Awards column are the totals from the Stock Awards and Option Awards columns set forth in the Summary Compensation Table. Amounts in the Inclusion of Equity Values column are set forth in the table further below.
Year
​ ​
Average Summary
Compensation Table
Total for Non-PEO
NEOs
($)
​ ​
Average Exclusion of
Stock Awards and
Option Awards for
Non-PEO NEOs
($)
​ ​
Average Inclusion of
Equity Values for
Non-PEO NEOs
($)
​ ​
Average
Compensation
Actually Paid
to Non-PEO
NEOs
($)
​
2024
​ ​ ​ ​ 2,004,458 ​ ​ ​ ​ ​ (922,579) ​ ​ ​ ​ ​ 603,254 ​ ​ ​ ​ ​ 1,685,133 ​ ​
The amounts in the Inclusion of Equity Values in the tables above are derived from the amounts set forth in the following tables:
Year
​ ​
Average
Year-End
Fair Value of
Equity
Awards
Granted
During Year
That
Remained
Unvested as of
Last Day of
Year for Non-
PEO NEOs
($)
​ ​
Average
Change in
Fair Value
from Last
Day of Prior
Year to Last
Day of Year
of Unvested
Equity
Awards for
Non-PEO
NEOs
($)
​ ​
Average
Vesting-Date
Fair Value of
Equity
Awards
Granted
During Year
that Vested
During Year
for Non-PEO
NEOs
($)
​ ​
Average
Change in
Fair Value
from Last
Day of Prior
Year to
Vesting Date
of Unvested
Equity
Awards that
Vested During
Year for Non-
PEO NEOs
($)
​ ​
Average Fair
Value at Last
Day of Prior
Year of
Equity
Awards
Forfeited
During Year
for Non-PEO
NEOs
($)
​ ​
Total −
Average
Inclusion
of
Equity
Values
for Non-
PEO
NEOs
($)
​
2024
​ ​ ​ ​ 1,006,487 ​ ​ ​ ​ ​ (168,509) ​ ​ ​ ​ ​ 58,719 ​ ​ ​ ​ ​ (293,443) ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ 603,254 ​ ​
       
Compensation Actually Paid vs. Total Shareholder Return
Relationship Between PEO and Non-PEO NEO Compensation Actually Paid and Company Total Shareholder Return (“TSR”)
The following chart sets forth the relationship between Compensation Actually Paid to our PEO, the average of Compensation Actually Paid to our Non-PEO NEOs, the Company’s cumulative TSR over the four most recently completed fiscal years, and the Nasdaq Biotechnology Index TSR over the same period.
[MISSING IMAGE: bc_companytsr-4c.jpg]
       
Compensation Actually Paid vs. Net Income
Relationship Between PEO and Non-PEO NEO Compensation Actually Paid and Net Earnings
The following chart sets forth the relationship between Compensation Actually Paid to our PEO, the average of Compensation Actually Paid to our Non-PEO NEOs, and our Net Earnings during the four most recently completed fiscal years.
[MISSING IMAGE: bc_netearning-4c.jpg]
Net Earnings included in the preceding chart is calculated in accordance with GAAP (Generally Accepted Accounting Principles). During 2021, 2022, 2023 and 2024, the Company recorded amortization expenses for intangible assets of $30.0 million, $82.6 million, $82.4 million and $78.0 million, respectively. The
level of amortization of intangible assets increased during 2021 and increased further in 2022 primarily due to the amortization of definitive-lived intangible assets acquired in the US WorldMeds and Adamas acquisitions.
       
Compensation Actually Paid vs. Company Selected Measure
Relationship Between PEO and Non-PEO NEO Compensation Actually Paid and Gross Product Sales
The following chart sets forth the relationship between Compensation Actually Paid to our PEO, the average of Compensation Actually Paid to our Non-PEO NEOs, and our Gross Product Sales during the four most recently completed fiscal years.
PEO and Average Non-PEO NEO Compensation Actually Paid
Versus Gross Product Sales
[MISSING IMAGE: bc_productsales-4c.jpg]
       
Total Shareholder Return Vs Peer Group
Relationship Between PEO and Non-PEO NEO Compensation Actually Paid and Company Total Shareholder Return (“TSR”)
The following chart sets forth the relationship between Compensation Actually Paid to our PEO, the average of Compensation Actually Paid to our Non-PEO NEOs, the Company’s cumulative TSR over the four most recently completed fiscal years, and the Nasdaq Biotechnology Index TSR over the same period.
[MISSING IMAGE: bc_companytsr-4c.jpg]
       
Tabular List, Table
The following table presents the financial performance measures that the Company considers the most important in linking Compensation Actually Paid to our PEO and Non-PEO NEOs for 2023 to Company performance. The measures in this table are not ranked.
​ ​
Gross Product Sales
​ ​
​ ​
Operating Earnings
​ ​
       
Total Shareholder Return Amount $ 152.45 122.01 150.38 122.93 106.07
Peer Group Total Shareholder Return Amount 118.2 118.87 113.65 126.45 126.42
Net Income (Loss) $ 73,900,000 $ 1,300,000 $ 60,700,000 $ 53,400,000 $ 127,000,000
Company Selected Measure Amount 1,101,000,000 1,071,000,000 1,181,000,000 1,021,000,000 951,000,000
PEO Name Jack Khattar        
Equity Awards Adjustments, Footnote
The amounts in the Inclusion of Equity Values in the tables above are derived from the amounts set forth in the following tables:
Year
​ ​
Year-End
Fair Value of
Equity
Awards
Granted
During Year
That
Remained
Unvested as
of Last Day
of Year for
Jack Khattar
($)
​ ​
Change in
Fair Value
from Last Day
of Prior Year
to Last Day of
Year of
Unvested
Equity
Awards for
Jack Khattar
($)
​ ​
Vesting-Date
Fair Value of
Equity
Awards
Granted
During Year
that Vested
During Year
for Jack
Khattar
($)
​ ​
Change in
Fair Value
from Last
Day of Prior
Year to
Vesting Date
of Unvested
Equity
Awards that
Vested
During Year
for Jack
Khattar
($)
​ ​
Fair Value at
Last Day of
Prior Year of
Equity
Awards
Forfeited
During Year
for Jack
Khattar
($)
​ ​
Total −
Inclusion
of
Equity
Values for
Jack
Khattar
($)
​
2024
​ ​ ​ ​ 10,504,593 ​ ​ ​ ​ ​ (2,103,882) ​ ​ ​ ​ ​ 1,375,198 ​ ​ ​ ​ ​ (2,411,941) ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ 7,363,968 ​ ​
Year
​ ​
Average
Year-End
Fair Value of
Equity
Awards
Granted
During Year
That
Remained
Unvested as of
Last Day of
Year for Non-
PEO NEOs
($)
​ ​
Average
Change in
Fair Value
from Last
Day of Prior
Year to Last
Day of Year
of Unvested
Equity
Awards for
Non-PEO
NEOs
($)
​ ​
Average
Vesting-Date
Fair Value of
Equity
Awards
Granted
During Year
that Vested
During Year
for Non-PEO
NEOs
($)
​ ​
Average
Change in
Fair Value
from Last
Day of Prior
Year to
Vesting Date
of Unvested
Equity
Awards that
Vested During
Year for Non-
PEO NEOs
($)
​ ​
Average Fair
Value at Last
Day of Prior
Year of
Equity
Awards
Forfeited
During Year
for Non-PEO
NEOs
($)
​ ​
Total −
Average
Inclusion
of
Equity
Values
for Non-
PEO
NEOs
($)
​
2024
​ ​ ​ ​ 1,006,487 ​ ​ ​ ​ ​ (168,509) ​ ​ ​ ​ ​ 58,719 ​ ​ ​ ​ ​ (293,443) ​ ​ ​ ​ ​ — ​ ​ ​ ​ ​ 603,254 ​ ​
       
Measure:: 1          
Pay vs Performance Disclosure          
Name Gross Product Sales        
Non-GAAP Measure Description
5.   We determined Gross Product Sales to be the most important financial performance measure used to link Company performance to Compensation Actually Paid to our PEO and Non-PEO NEOs in 2024, 2023 and 2022. This performance measure may not have been the most important financial performance measure for years prior and we may determine a different financial performance measure to be the most important financial performance measure in future years. The Company’s net revenues consist of net product sales and royalties, licensing and other revenues. The Company recognizes revenue from product sales in an amount that reflects the consideration the Company expects to ultimately receive in exchange for those goods. The Company recognizes gross product sales when its customers take control of its products, including title and ownership. Product sales are recorded net of various forms of variable consideration, including: provision for estimated rebates; provision for estimated future product returns; and an estimated provision for discounts. These are collectively considered “sales deductions.” These amounts are treated as variable consideration, estimated and recognized as a reduction of the transaction price at the time of sale.
       
Measure:: 2          
Pay vs Performance Disclosure          
Name Operating Earnings        
PEO | Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount $ (10,766,439)        
PEO | Equity Awards Adjustments, Excluding Value Reported in Compensation Table          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount 7,363,968        
PEO | Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount 10,504,593        
PEO | Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount (2,103,882)        
PEO | Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount 1,375,198        
PEO | Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount (2,411,941)        
PEO | Fair Value at Last Day of Prior Year of Equity Awards Forfeited During Year [Member]          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount        
Non-PEO NEO | Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount (922,579)        
Non-PEO NEO | Equity Awards Adjustments, Excluding Value Reported in Compensation Table          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount 603,254        
Non-PEO NEO | Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount 1,006,487        
Non-PEO NEO | Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount (168,509)        
Non-PEO NEO | Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount 58,719        
Non-PEO NEO | Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount (293,443)        
Non-PEO NEO | Fair Value at Last Day of Prior Year of Equity Awards Forfeited During Year [Member]          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount